145 related articles for article (PubMed ID: 1709237)
21. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia.
Jackman WM; Friday KJ; Fitzgerald DM; Yeung-Lai-Wah JA; Lazzara R
Am J Cardiol; 1988 Dec; 62(19):8L-19L. PubMed ID: 3059792
[TBL] [Abstract][Full Text] [Related]
22. Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for termination of paroxysmal supraventricular tachycardia.
Gambhir DS; Bhargava M; Arora R; Khalilullah M
Indian Heart J; 1995; 47(3):237-43. PubMed ID: 7558090
[TBL] [Abstract][Full Text] [Related]
23. Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia.
Fujiki A; Mizumaki K; Tani M; Yoshida S; Sasayama S
J Cardiovasc Pharmacol; 1992 Sep; 20(3):375-9. PubMed ID: 1279281
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Sahar DI; Reiffel JA; Bigger JT; Squatrito A; Kidwell GA
Am Heart J; 1989 Mar; 117(3):562-8. PubMed ID: 2919535
[TBL] [Abstract][Full Text] [Related]
25. [Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia].
Vester EG
Herz; 1997 Jun; 22 Suppl 1():40-50. PubMed ID: 9333591
[TBL] [Abstract][Full Text] [Related]
26. [Electrophysiologic effect of a new Ca(2+)-antagonist, TA-3090 on supraventricular tachycardia and conduction system].
Tanno K; Kobayashi Y; Miyata A; Chiyoda K; Nakagawa H; Kurano K; Kikushima S; Yazawa T; Baba T; Mukai H
Kokyu To Junkan; 1992 Sep; 40(9):897-902. PubMed ID: 1439290
[TBL] [Abstract][Full Text] [Related]
27. [Electrophysiological effects and clinical efficacy of flecainide in childhood patients with supraventricular reciprocating paroxysmal tachycardia].
Musto B; D'Onofrio A; Cavallaro C; Musto A; Della Gatta O; Marsico F
G Ital Cardiol; 1987 May; 17(5):444-9. PubMed ID: 3115857
[TBL] [Abstract][Full Text] [Related]
28. Initial onset of accessory pathway-mediated and atrioventricular node reentrant tachycardia after age 65: clinical features, electrophysiologic characteristics, and possible facilitating factors.
Chen SA; Lee SH; Wu TJ; Chiang CE; Cheng CC; Tai CT; Chiou CW; Ueng KC; Wen ZC; Chang MS
J Am Geriatr Soc; 1995 Dec; 43(12):1370-7. PubMed ID: 7490388
[TBL] [Abstract][Full Text] [Related]
29. Cardiac electrophysiology of the antiarrhythmic agent recainam (Wy-42,362) in anesthetized dogs: relation to plasma and myocardial concentrations.
Colatsky TJ; Bird LB; Knowles JA
J Cardiovasc Pharmacol; 1988 Mar; 11(3):308-16. PubMed ID: 2452923
[TBL] [Abstract][Full Text] [Related]
30. [Use of digoxin in patients with paroxysmal supraventricular tachycardia].
Smetnev AS; Titov VN; Shevchenko NM; Gurevich EM
Kardiologiia; 1989 Apr; 29(4):61-4. PubMed ID: 2666709
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
[TBL] [Abstract][Full Text] [Related]
32. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction.
Feld GK; Venkatesh N; Singh BN
J Cardiovasc Pharmacol; 1988 May; 11(5):573-80. PubMed ID: 2455844
[TBL] [Abstract][Full Text] [Related]
33. Clinical, electrophysiologic and antiarrhythmic efficacy of moricizine HCl.
Smetnev AS; Shugushev KKh; Rosenshtraukh LV
Am J Cardiol; 1987 Oct; 60(11):40F-44F. PubMed ID: 3310584
[TBL] [Abstract][Full Text] [Related]
34. Electrophysiology and long-term efficacy of pentisomide in patients with supraventricular tachycardia.
Kühlkamp V; Mewis C; Seipel L
Int J Cardiol; 1992 Jul; 36(1):69-79. PubMed ID: 1428255
[TBL] [Abstract][Full Text] [Related]
35. Electrophysiologic effects of oral propafenone in Wolff-Parkinson-White syndrome studied by programmed electrical stimulation.
Sethi KK; Prasad GS; Mohan JC; Arora R; Khalilullah M
Indian Heart J; 1991; 43(1):5-10. PubMed ID: 1894303
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.
Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ
Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688
[TBL] [Abstract][Full Text] [Related]
37. Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
Hammill SC; McLaran CJ; Wood DL; Osborn MJ; Gersh BJ; Holmes DR
J Am Coll Cardiol; 1987 Jun; 9(6):1364-8. PubMed ID: 3584724
[TBL] [Abstract][Full Text] [Related]
38. Pirmenol in termination of paroxysmal supraventricular tachycardia.
Toivonen LK
Clin Cardiol; 1986 Aug; 9(8):369-73. PubMed ID: 3731562
[TBL] [Abstract][Full Text] [Related]
39. Role of intravenous isoproterenol in the electrophysiologic induction of atrioventricular node reentrant tachycardia in patients with dual atrioventricular node pathways.
Huycke EC; Lai WT; Nguyen NX; Keung EC; Sung RJ
Am J Cardiol; 1989 Nov; 64(18):1131-7. PubMed ID: 2479251
[TBL] [Abstract][Full Text] [Related]
40. Sustained symptomatic sinus node reentrant tachycardia: incidence, clinical significance, electrophysiologic observations and the effects of antiarrhythmic agents.
Gomes JA; Hariman RJ; Kang PS; Chowdry IH
J Am Coll Cardiol; 1985 Jan; 5(1):45-57. PubMed ID: 3964808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
